Analysts and portfolio managers can access a live webcast of the presentation by visiting www.analyst-conference.com and clicking on the analyst/pm registration tab. A replay will be available for 30 days following the conference.
Some of the recent key developments for
Bionovo'sdrug candidates include: MF101 -- An independent physician survey shows strong evidence that, if approved, Menerba(TM) (MF101) could become first-line treatment for menopausal symptoms. This suggests that Menerba could take a leading position in a multi-billion dollar market. -- Bionovoannounced that it has developed a novel analytical 2-dimensional liquid chromatography mass spectrometry-based (LC/LC-MS/MS) multiplexing platform that allows for the rapid, specific, sensitive automated quantification of the active pharmaceutical compounds of Menerba. If applied to botanical drug product production, this technique should facilitate exquisite batch-to-batch consistency and control of the final drug product. -- Multiple papers were presented to the Endocrine Societyindicating that estrogen receptor beta may have a role in cancer prevention - suggesting that Menerba may have an ultimate role in cancer treatment beyond its current proposed indication for menopausal hot flashes. -- Also presented at the Endocrine Societywas a study describing the development of a neural model for thermoregulation in the brain, providing more specific scientific support for Menerba's mechanism of action and efficacy potential. -- Bionovoannounced that further analysis of the data from its successfully completed phase 2 study of Menerba showed that Menerba was able to reduce "night awakenings" from menopausal hot flashes at a statistically significant level. This sign of efficacy in the most debilitating aspect of hot flashes is further evidence that Menerba may provide an unmatched combination of safety and efficacy in comparison to other treatments being developed or currently on the market. BZL101 and other Cancer Drug Candidates -- A peer-reviewed study published in the journal Cancer Biology and Treatment, described the powerful and selective mechanism of action for BZL101 in cancer tumors. -- Another study was presented at American Association for Cancer Research(AACR) that detailed the unique mechanisms of action for two other Bionovodrug candidates for the treatment of cancer, BN107 and BN108. -- Results from a second clinical study of BZL101 in advanced breast cancer was presented at ASCO, indicating BZL101's favorable tolerability and safety profile, and exhibiting encouraging signs of positive efficacy. -- Further results from this study were presented to the Society of Integrative Oncology(SIO), where the abstract was the highest scoring abstract. -- Additional studies of BN107 and BN108 were presented at the San Antonio Breast Cancer Symposium, indicating promising signs of potential efficacy for both cancer drug candidates. VG101 -- Laboratory studies were presented at the 7th Annual Oxford International Conference on the Science of Botanicals & American Society of Pharmacognosy4th Interim Meeting, describing the structural elucidation of active estrogen receptor beta selective compounds from VG101, Bionovo'sdrug candidate for vaginal atrophy. This structural elucidation is key to the development of the drug candidate's mechanism of action and intellectual property protection. -- In vivo safety and efficacy data were presented to the Endocrine Society, indicating VG101 may have superior clinical activity to existing drug products for the treatment of menopausal vaginal dryness. -- This data was further detailed to the North American Menopause Society(NAMS), indicating that VG101 may well provide superior efficacy and safety versus estrogen therapy.
Forward Looking Statements
This release contains certain forward-looking statements relating to the
Claire Fong Tom ChestermanTel: 510.601.2000 firstname.lastname@example.org Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLCTel: 602.889.9700 email@example.com